Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
NovoCure Ltd reported first quarter ended March 31, 2026 results: revenue Total net revenues for the quarter were $174.1 million, net income Net loss for the quarter was $71.1 million, EPS loss per share of $0.62.
- Period
- first quarter ended March 31, 2026
- Revenue
- Total net revenues for the quarter were $174.1 million
- Net income
- Net loss for the quarter was $71.1 million
- EPS
- loss per share of $0.62
- Result
- reported results
Exact text from the filing
Novocure Reports First Quarter 2026 Financial Results Quarterly net revenues of $174 million, up 12% year-over-year, driven by global growth in Optune Gio ® Optune Pax® approved by the U.S. FDA and launched for the treatment of locally advanced pancreatic cancer; more than 800 prescribers certified and more than 160 prescriptions received through March 31, 2026 BAAR, Switzerland – April 30, 2026 - Novocure (NASDAQ: NVCR) today reported financial results for the first quarter that ended March 31, 2026.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
NovoCure Ltd reported full year 2026 results: revenue Total net revenue: $690 million - $710 million (previous: $675 million - $705 million). Guidance raised.
- Period
- full year 2026
- Revenue
- Total net revenue: $690 million - $710 million (previous: $675 million - $705 million)
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
Novocure’s updated guidance for the full year 2026, as of April 30, 2026, is summarized below: • Total net revenue: $690 million - $710 million (previous: $675 million - $705 million) • Adjusted EBITDA*: $(15) million - $0 million (previous: $(20) million - $0 million)
View on SEC.gov